Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EBT (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of EBT data on record, last reported at $111.6 million in Q4 2025.

  • For Q4 2025, EBT rose 395.29% year-over-year to $111.6 million; the TTM value through Dec 2025 reached -$112000.0, up 99.96%, while the annual FY2025 figure was -$112000.0, 99.96% up from the prior year.
  • EBT reached $111.6 million in Q4 2025 per AMLX's latest filing, up from -$34.4 million in the prior quarter.
  • Across five years, EBT topped out at $111.6 million in Q4 2025 and bottomed at -$118.6 million in Q1 2024.
  • Average EBT over 5 years is -$26.8 million, with a median of -$35.1 million recorded in 2025.
  • Peak YoY movement for EBT: tumbled 8549.82% in 2024, then soared 395.29% in 2025.
  • A 5-year view of EBT shows it stood at -$28.3 million in 2021, then tumbled by 52.51% to -$43.2 million in 2022, then surged by 110.28% to $4.4 million in 2023, then plummeted by 951.01% to -$37.8 million in 2024, then skyrocketed by 395.29% to $111.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $111.6 million in Q4 2025, -$34.4 million in Q3 2025, and -$41.4 million in Q2 2025.